Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05349877
Other study ID # PUCRSBR-10098
Secondary ID 39059120.0.0000.
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 10, 2022
Est. completion date December 15, 2022

Study information

Verified date October 2021
Source Pontificia Universidade Católica do Rio Grande do Sul
Contact Angelo B Costa, PhD
Phone +55 51 98405-4408
Email angelobrandellicosta@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Experiences of violence, from micro to physical aggressions, have a deleterious impact on mental health. According to the Minority Stress Theory, unfavorable social conditions (such as anticipated and experienced discrimination and internalized homophobia), mediated by resilience strategies, can lead to mental health or illness. Sexual and gender minorities (SGM) face stigma and discrimination aggravating multiple aspects of their lives: from school drop-out to halting health care access. SGM reveal avoiding medical assistance for fear of discrimination while health professionals disclose feeling unprepared to handle SGM health needs. There are two main challenges: 1) developing specific psychological interventions to reduce the impact of stigma and discrimination on SGM' mental health; and 2) training public health professionals to properly address SGM needs. Therefore, the present trial aims to assess the efficacy of a brief, self-guided, on-line, asynchronous and unsupervised psychological intervention in improving SGM' mental health.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 306
Est. completion date December 15, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 16 Years to 100 Years
Eligibility Inclusion Criteria: - Self-identity as sexual and gender minority. - Being older than 16 years old. - Have a stable on-line connection for, at least, 20 minutes in a place where won't be disturbed. - Reports, in the baseline survey, previous experiences of discrimination, having depression or anxiety symptoms. - Currently living in Rio Grande do Sul. Exclusion Criteria: - Disagrees with the consent form.

Study Design


Intervention

Behavioral:
Expressive writing
Write, continuously for 20 minutes, about deepest emotions and thoughts concerning experiences of minority stress, exploring a particular event and how it has affected the participant.
Self-affirmation
Write, continuously for 20 minutes, about values the participant think is important to overcome experiences of minority stress.
Placebo
Write, continuously for 20 minutes, about their daily routine, without expressing feelings and deep thoughts about it.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Pontificia Universidade Católica do Rio Grande do Sul

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline depression at 3 and 6 moths after the intervention. Assessed using the Center for Epidemiologic Studies - Depression (CES-D). CES-D is composed of 20 items. The final score ranges from 0 to 60 points. Originally, the cutoff point of the CES-D scale to identify the presence of depressive symptoms is equal or higher 16 points. However, when considering Brazilian samples, the cutoff point of equal or higher 12 points was proposed. Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
Primary Change from baseline anxiety at 1 week, and 3 and 6 moths after the intervention. Evaluated using the Generalized Anxiety Disorder 7-item (GAD-7). The GAD-7 consists of 7 questions based in part on the DSM-IV criteria for GAD and reflects the frequency of symptoms during the preceding 2-week period. The GAD-7 requires approximately 1-2 minutes to administer and for each symptom queried provides the following response options: "not at all," "several days," "over half the days" and "nearly every day" and these are scored, respectively, as 0, 1, 2 or 3. A score of 10 or greater on the GAD-7 represents a reasonable cut point for identifying cases of GAD. Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
Primary Change from baseline social phobia at 1 week, and 3 and 6 moths after the intervention. Evaluated using the Social Avoidance and Distress Scale (SADS). SADS is a 28 item true/false scale that measures measures aspects of social anxiety including distress, discomfort, fear and avoidance. A total score on the SADS is obtained based on the answers to the true/false questions. Higher scores indicate greater social anxiety. Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
Primary Change from baseline post-traumatic stress at 1 week, and 3 and 6 moths after the intervention. Post-Traumatic Stress Disorder Checklist - Civilian Version (PCL-C). The PCL-C is a 17-item self-report checklist of PTSD symptoms based closely on the DSM-IV criteria. The score consists in adding up all items from each of the 17 items for a total severity score (range = 17-85). The cut off 17-29 shows little to no severity, 28-29 suggests some PTSD symptom, 30-44 moderate to moderately high severity of PTSD symptoms, and 45-85 high severity of PTSD symptoms. Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
Primary Change from baseline on suicide ideation at 3 and 6 moths after the intervention. Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a clinically-validated screening tool that healthcare providers use to screen for depression, and also to diagnose and monitor the severity of the condition. A PHQ-9 score total of 0-4 points equals "normal" or minimal depression. Scoring between 5-9 points indicates mild depression, 10-14 points indicates moderate depression, 15-19 points indicates moderately severe depression, and 20 or more points indicates severe depression. Baseline (T0), three months after the intervention (T2), and six the intervention (T3).
Primary Change from baseline on substance use at 3 and 6 moths after the intervention. Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) is an 8 questions tool that detects substance use and related problems. A 'global continuum of risk score' (or total substance involvement) is calculated by the addition of all items for all substances on the ASSIST and has a maximum score of 208. Baseline (T0), three months after the intervention (T2), and six the intervention (T3).
Primary Change from baseline on sex risk behaviors at 3 and 6 moths after the intervention. Inquired using yes-no questions concerning unprotected intercourse and multiple sex partners, as well as the Perceived Risk of HIV Scale. Perceived Risk of HIV Scale is a self-report 8-item measure developed to assess how people think and feel about their risk of HIV infection based on their previous sexual behavior and covering several dimensions of perceived HIV risk. Higher scores are associated with a greater number of sex partners, episodes of unprotected sex and having sex while high. Baseline (T0), three months after the intervention (T2), and six the intervention (T3).
Secondary Change from baseline on resilience at 1 week, and 3 and 6 moths after the intervention. Wagnild and Youngs's Resilience Scale that has presented the following scoring for the total score: 25-100 = Very low, 101-115 = Low, 116-130 = On the low end, 131-145 = Moderate, 146-160 = Moderately high, and 161-175 = High. Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
Secondary Change from baseline on self-esteem at 1 week, and 3 and 6 moths after the intervention. Rosenberg Self-Esteem Scale. The scale ranges from 0-30. Scores between 15 and 25 are within normal range; scores below 15 suggest low self-esteem. Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A